Tirzepatide (Mounjaro) vs Tirzepatide (Zepbound)

Because Mounjaro and Zepbound contain the same molecule, their pharmacological efficacy is fundamentally the same — the differences lie in the clinical trial programs and approved indications ^[1][2].

Mounjaro was studied in the SURPASS program for type 2 diabetes. Across SURPASS-1 through SURPASS-5, tirzepatide demonstrated HbA1c reductions of 1.87% to 2.58% and weight loss of 5.4 kg to 12.9 kg depending on dose and study population ^[6][4]. In SURPASS-2, the head-to-head trial versus semaglutide 1 mg, tirzepatide showed superior glycemic control and weight loss at all three doses (5 mg, 10 mg, 15 mg) ^[4]. The percentage of patients achieving HbA1c below 5.7% (normal range) was 27-46% with tirzepatide, a remarkable result for a diabetes medication ^[4].

Zepbound was studied in the SURMOUNT program for weight management. In SURMOUNT-1, which enrolled adults with obesity without type 2 diabetes, tirzepatide produced weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) of body weight over 72 weeks ^[3]. SURMOUNT-2 studied patients with both type 2 diabetes and obesity, showing weight loss of 12.8% (10 mg) and 14.7% (15 mg) over 72 weeks ^[5]. SURMOUNT-4 demonstrated that continued treatment maintained weight loss while discontinuation led to regain ^[9].

The key clinical distinction is the primary endpoint: Mounjaro trials focused on HbA1c reduction with weight loss as secondary, while Zepbound trials focused on weight loss as the primary endpoint ^[4][3]. Both dose ranges overlap (5 mg, 10 mg, 15 mg maximum), though prescribing patterns may differ based on the target indication.

In practice, the same dose of tirzepatide will produce the same physiological effects regardless of whether it is prescribed as Mounjaro or Zepbound ^[1][2]. The distinction is regulatory and commercial, not pharmacological.

Since Mounjaro and Zepbound contain the identical active ingredient at the same doses, their side effect profiles are essentially the same ^[1][2].

Across the SURPASS and SURMOUNT clinical trial programs, the most commonly reported adverse events were gastrointestinal ^[3][4][6]. Nausea occurred in 12-33% of patients (depending on dose and study), diarrhea in 12-25%, constipation in 6-17%, vomiting in 5-13%, and decreased appetite in 5-11% ^[1][2]. Injection site reactions occurred in 3-7% of patients ^[1][2].

Treatment discontinuation due to adverse events ranged from 3-7% across trials, which is comparable to other GLP-1-based therapies ^[3][4]. Most gastrointestinal side effects were mild to moderate in severity and tended to diminish during the dose escalation period and after reaching the maintenance dose ^[1][2].

Both Mounjaro and Zepbound carry the same FDA boxed warning regarding thyroid C-cell tumors based on rodent studies, and both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[1][2].

Shared warnings include pancreatitis, acute gallbladder disease (cholecystitis, cholelithiasis), hypoglycemia (particularly when combined with insulin or sulfonylureas), acute kidney injury, hypersensitivity reactions (anaphylaxis, angioedema), and suicidal ideation or behavior ^[1][2]. The FDA has been monitoring post-market reports of suicidal thoughts with all GLP-1-based medications.

Because the molecules are identical, patients who experience side effects with one formulation should expect the same with the other ^[1][2].

Mounjaro and Zepbound differ primarily in list price and insurance coverage patterns, which reflects their different approved indications rather than any difference in the medication itself ^[1][2].

Mounjaro has a list price of approximately $1,023-$1,100 per month ^[1]. Zepbound launched at a list price of approximately $1,060 per month ^[2]. These prices are quite similar.

The critical cost difference lies in insurance coverage. Mounjaro, approved for type 2 diabetes, is covered by most commercial insurance plans and Medicare Part D, though prior authorization is often required ^[8]. Zepbound, approved for weight management, faces the same coverage challenges as other anti-obesity medications — many plans exclude it, and Medicare Part D has historically not covered weight loss drugs ^[7].

Eli Lilly offers savings programs for both products ^[10]. The Mounjaro Savings Card and Zepbound Savings Card can each reduce costs to as low as $25 per fill for eligible commercially insured patients. For patients paying cash, Eli Lilly's LillyDirect program may offer Zepbound at reduced prices ^[10].

Some patients with both type 2 diabetes and obesity may have coverage for Mounjaro but not Zepbound. In such cases, Mounjaro would be prescribed with the dual benefit of glycemic control and weight management, since the molecule is the same ^[1][2].

Mounjaro and Zepbound use the identical Eli Lilly single-dose autoinjector device and are available in the same dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg ^[1][2]. Both are administered as once-weekly subcutaneous injections.

The autoinjector device is designed for simplicity: the patient places it flat against the skin (abdomen, thigh, or upper arm), unlocks it, and presses the button ^[1][2]. The injection is completed automatically.

Both require refrigeration before first use (36F to 46F) and can be stored at room temperature (up to 86F) for up to 21 days ^[1][2]. The titration schedules are similar, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks as tolerated ^[1][2].

In terms of convenience, there is no meaningful difference between Mounjaro and Zepbound. The packaging and device design are functionally identical ^[1][2].

The choice between Mounjaro and Zepbound is primarily determined by your medical diagnosis, not by medication preference, since both contain tirzepatide ^[1][2].

If you have type 2 diabetes (with or without obesity), Mounjaro is the FDA-approved option ^[1][8]. Your healthcare provider will prescribe Mounjaro for glycemic control, and you will likely experience significant weight loss as an additional benefit ^[4]. Insurance coverage for Mounjaro is generally more accessible for the diabetes indication.

If you do not have type 2 diabetes but meet the criteria for chronic weight management (BMI >=30, or BMI >=27 with a weight-related comorbidity), Zepbound is the FDA-approved option ^[2][7]. However, insurance coverage for anti-obesity medications remains a significant barrier, and out-of-pocket costs may be higher.

For patients with both type 2 diabetes and obesity, the choice may come down to which indication your provider documents and which your insurance covers ^[1][2]. Because the molecule is the same, the clinical effect will be identical regardless of which brand name appears on the prescription.

It is important to emphasize that you should not take both Mounjaro and Zepbound simultaneously, as they contain the same active ingredient and combining them would result in overdose ^[1][2].

This information is for educational purposes only and does not constitute medical advice. Consult your healthcare provider to determine which medication is appropriate for your diagnosis and treatment goals.